Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor

N Engl J Med. 1972 Jan 6;286(1):8-14. doi: 10.1056/NEJM197201062860102.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Biotransformation / drug effects
  • Brain / drug effects*
  • Carbon Monoxide Poisoning / drug therapy
  • Cerebral Palsy / drug therapy
  • Child
  • Clinical Trials as Topic
  • Dihydroxyphenylalanine / administration & dosage
  • Dihydroxyphenylalanine / adverse effects
  • Dihydroxyphenylalanine / metabolism
  • Dihydroxyphenylalanine / pharmacology
  • Dihydroxyphenylalanine / therapeutic use*
  • Dopamine / metabolism
  • Dopamine / urine
  • Drug Synergism*
  • Female
  • Humans
  • Hydrazines / therapeutic use
  • Male
  • Methyldopa / administration & dosage
  • Methyldopa / pharmacology
  • Methyldopa / therapeutic use
  • Neurologic Examination
  • Neuromuscular Diseases / drug therapy
  • Parkinson Disease / drug therapy*
  • Phenylacetates / urine
  • Pyridoxine / administration & dosage
  • Pyridoxine / pharmacology
  • Time Factors

Substances

  • Hydrazines
  • Phenylacetates
  • Methyldopa
  • Dihydroxyphenylalanine
  • Pyridoxine
  • Dopamine